These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38406521)

  • 1. From primary myelofibrosis to chronic myeloid leukemia,
    Wang D; Kamata W; Ye F; You MJ
    EJHaem; 2024 Feb; 5(1):157-161. PubMed ID: 38406521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
    Shi XB; Jiang JF; Jin FX; Cheng W
    World J Clin Cases; 2019 May; 7(9):1087-1092. PubMed ID: 31123683
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhang Y; Bi H; Wang Y; Chen L; Pan J; Xu P; Wang W; Yang S
    Blood Sci; 2022 Oct; 4(4):199-204. PubMed ID: 36518237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of
    Lorenzo M; Grille S; Stevenazzi M
    J Hematol; 2020 Apr; 9(1-2):23-29. PubMed ID: 32362982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
    Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
    Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
    Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
    Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
    Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
    Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
    Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
    Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
    BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Tarantini F; Cumbo C; Zagaria A; Parciante E; Anelli L; Coccaro N; Tota G; Minervini CF; Redavid I; Rossi AR; Conserva MR; Specchia G; Musto P; Albano F
    Hematology; 2022 Dec; 27(1):842-846. PubMed ID: 35938951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.
    Brattås MK; Lilleeng K; Hovland R; Lægreid IJ; Vorland M; Leh F; Bruserud Ø; Gjertsen BT; Reikvam H
    Biomark Res; 2018; 6():33. PubMed ID: 30479769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
    Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].
    Yuan XG; Wan RT; Zhao XW; Yang XZ; Xiao J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1236-1241. PubMed ID: 34362508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurrence of
    Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
    Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.
    Ahmad N; Qayum S; Jameel A; Ali A; Siraj S; Ali J; Yousafzai YM
    Pak J Pharm Sci; 2021 Nov; 34(6(Supplementary)):2289-2295. PubMed ID: 35039265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
    Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.